StockData
Instil Bio, Inc. logo

Instil Bio, Inc. (TIL) stock

TILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$5.40−0.35 (-6.09%)

Close on Nov 17, 2026Market cap $36.62MP/E –Yield –

Instil Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Instil Bio's operating income for the twelve months ending Jun 30, 2026 was -$37.17M. For fiscal 2025 it was -$78.58M. The highest annual figure on record is -$33.64M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$78.58M–
FY2024Dec 31, 2024-$73.54M–
FY2023Dec 31, 2023-$159.17M–
FY2022Dec 31, 2022-$226.46M–
FY2021Dec 31, 2021-$155.56M–
FY2020Dec 31, 2020-$33.64M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.58M–
Q1 FY2026Mar 31, 2026-$7.01M–
Q4 FY2025Dec 31, 2025-$9.56M–
Q3 FY2025Sep 30, 2025-$15.02M–
Q2 FY2025Jun 30, 2025-$23.44M–
Q1 FY2025Mar 31, 2025-$30.56M–
Q4 FY2024Dec 31, 2024-$11.82M–
Q3 FY2024Sep 30, 2024-$23.63M–
Q2 FY2024Jun 30, 2024-$14.14M–
Q1 FY2024Mar 31, 2024-$23.96M–
Q4 FY2023Dec 31, 2023-$13.02M–
Q3 FY2023Sep 30, 2023-$66.72M–
Q2 FY2023Jun 30, 2023-$20.99M–
Q1 FY2023Mar 31, 2023-$58.45M–
Q4 FY2022Dec 31, 2022-$56.80M–
Q3 FY2022Sep 30, 2022-$56.65M–
Q2 FY2022Jun 30, 2022-$58.72M–
Q1 FY2022Mar 31, 2022-$54.29M–
Q4 FY2021Dec 31, 2021-$53.75M–
Q3 FY2021Sep 30, 2021-$43.02M–
Q2 FY2021Jun 30, 2021-$35.38M–
Q1 FY2021Mar 31, 2021-$23.40M–
Q4 FY2020Dec 31, 2020-$17.48M–
Q3 FY2020Sep 30, 2020-$7.71M–
Q2 FY2020Jun 30, 2020-$4.59M–
Q1 FY2020Mar 31, 2020-$3.86M–

More Instil Bio figures

See a number that looks wrong?